A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Lepage, Chris ^a   Smith, Andra M ^a   Moreau, Jeremy ^a   Barlow Krelina, Emily ^a   Wallis, Nancy ^a   Collins, Barbara ^a,b   MacKenzie, Joyce ^b   Scherling, Carole ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Chemotherapy; Cognition; MRI; Neuroimaging; Voxel based morphometry

Indexed keywords

EID: 84920120453     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-444     Document Type: Article

References (73)

1. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott L, Skalla K, Whedon M, Bivens S, Mitchell T, Greenberg E, Silberfarb P: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.J Clin Oncol 2002, 20:485–493.
2. Ahles TA, Saykin AJ, McDonald BC, Furstenberg C, Cole B, Hanscom B, Mulrooney T, Schwartz G, Kaufman P: Cognitive function in breast cancer patients prior to adjuvant treatment.Breast Cancer Res Treat 2007, 110:143–152.
3. Andersson JLR, Jenkinson M, Smith S: Non-linear registration aka spatial normalisation FMRIB Technial Report TR07JA2. 2007.http://www.fmrib.ox.ac.uk/analysis/techrep/
4. Army US: Army Individual Test Battery: Manual for Directions and Scoring. War Department, Adjutant General’s Office, Washington, DC; 1944.
5. Ashburner J, Friston KJ: Voxel-based morphometry–the methods.Neuroimage 2000, 11:805–821.
6. Augustine JR: Circuitry and functional aspects of the insular lobe in primates including humans.Brain Res Brain Res Rev 1996, 22:229–244.
7. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review.J Pain Symptom Manage 2001, 21:407–424.
8. Benedict R: Brief Visuospatial Memory Test—Revised Professional Manual. Psychological Assessment Resources, Lutz, FL; 1997.
9. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing.J R Stat Soc Series B Stat Methodol 1995, 57:289–300.
10. Bergouignan L, Lefranc JP, Chupin M, Morel N, Spano JP, Fossati P: Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval.PLoS One 2011, 6:e25349.
11. Boykoff N, Moieni M, Subramanian SK: Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response.J Cancer Surviv 2009, 3:223–232.
12. Brandt J, Benedict R: Hopkins Verbal Learning Test—Revised Professional Manual. Psychological Assessment Resources, Lutz, FL; 2001.
13. Brown J: Some tests of the decay theory of immediate memory.Q J Exp Psychol 1958, 10:12–21.
14. Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A: Cognitive effects of chemotherapy in breast cancer patients: a dose–response study.Psychooncology 2013, 22:1517–1527.
15. Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Klaunig JE, Champion VL, Unverzagt FW, Saykin AJ: Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage.Breast Cancer Res Treat 2012, 137:493–502.
16. De Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FSAM, Schagen SB: Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.Hum Brain Mapp 2011, 33:2971–2983.
17. De Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FSAM, Nederveen EB, Schagen SB: Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.Hum Brain Mapp 2011, 32:1206–1219.
18. Delis D, Kaplan E, Kramer J: Delis Kaplan Executive Function System Test Manual. Psychological Corporation, San Antonio, TX; 2001.
19. Dietrich J: Chemotherapy associated central nervous system damage.Adv Exp Med Biol 2010, 678:77–85.
20. Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, James S, Voets N, Watkins K, Matthews PM, James A: Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia.Brain 2007, 130:2375–2386.
21. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips K-A: The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.Brain Cogn 2005, 59:60–70.
22. Fan HGM, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock IF: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.J Clin Oncol 2005, 23:8025–8032.
23. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA: Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.J Clin Oncol 2007, 25:3866–3870.
24. Fischer J, Jak A, Kniker J, Rudick RA, Cutter G: Administration and Scoring Manual for the Multiple Sclerosis Functional Composite Measure (MSFC). National Multiple Sclerosis Society, New York; 2001.
25. Fletcher PC, Henson RNA: Frontal lobes and human memory insights from functional neuroimaging.Brain 2001, 124:849–881.
26. Flynn FG: Anatomy of the insula functional and clinical correlates.Aphasiology 1999, 13:55–78.
27. Good C, Johnsrude I, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ: A voxel-based morphometric study of ageing in 465 normal adult human brains.NeuroImage 2001, 14:21–36.
28. Gualtieri CT, Johnson LG: Reliability and validity of a computerized neurocognitive test battery, CNS vital signs.Arch Clin Neuropsychol 2006, 21:623–643.
29. Gualtieri CT, Johnson LG: A computerized test battery sensitive to mild and severe brain injury.Medscape J Med 2008, 10:90.
30. Hakamata Y, Matsuoka Y, Inagaki M, Nagamine M, Hara E, Imoto S, Murakami K, Kim Y, Uchitomi Y: Structure of orbitofrontal cortex and its longitudinal course in cancer-related post-traumatic stress disorder.Neurosci Res 2007, 59:383–389.
31. Horn NR, Dolan M, Elliott R, Deakin JF, Woodruff PW: Response inhibition and impulsivity: an fMRI study.Neuropsychologia 2003, 41:1959–1966.
32. Hosseini SMH, Koovakkattu D, Kesler SR: Altered small-world properties of gray matter networks in breast cancer.BMC Neurol 2012, 12:28.
33. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y: Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy.Cancer 2007, 109:146–156.
34. Jim HSL, Phillips KM, Chait S, Faul L, Popa M, Lee Y-H, Hussin M, Jacobsen P, Small B: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.J Clin Oncol 2012, 30:3578–3587.
35. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D: Regional brain activation during verbal declarative memory in metastatic breast cancer.Clin Cancer Res 2009, 15:6665–6673.
36. Kesler SR, Kent JS, O’Hara R: Prefrontal cortex and executive function impairments in primary breast cancer.Arch Neurol 2011, 68:1447–1453.
37. Kesler S, Janelsins M, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS: Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.Brain Behav Immun 2013,30(Suppl):S109-S116.
38. Koppelmans V, de Ruiter MB, van der Lijn F, et al.: Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.Breast Cancer Res Treat 2011, 132:1099–1106.
39. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen S: Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.J Clin Oncol 2012, 30:1080–1086.
40. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS: Neuropsychological Assessment. 4th edition. Oxford University Press, New York; 2004.
41. López Zunini RA, Scherling C, Wallis N, Collins B, MacKenzie J, Bielajew C, Smith AM: Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study.Brain Imaging Behav 2013, 7:460–477.
42. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH: An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.Neuroimage 2003, 19:1233–1239.
43. Maldjian JA, Laurienti PJ, Burdette JH: Precentral gyrus discrepancy in electronic versions of the Talairach atlas.Neuroimage 2004, 21:450–455.
44. McDonald BC, Saykin AJ: Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations.Brain Imaging Behav 2013, 7:374–387.
45. McDonald BC, Conroy SK, Ahles TA, West J, Saykin A: Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.Breast Cancer Res Treat 2010, 123:819–828.
46. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ: Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.Brain Behav Immun 2012,30(Suppl):S117-S125.
47. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ: Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study.J Clin Oncol 2012, 30:2500–2508.
48. O’Farrell E, MacKenzie J, Collins B: Clearing the air: a review of our current understanding of “chemo fog”.Curr Oncol Rep 2013, 15:260–269.
49. Plassmann H, O’Doherty JP, Rangel A: Appetitive and aversive goal values are encoded in the medial orbitofrontal cortex at the time of decision making.J Neurosci 2010, 30:10799–10808.
50. Quesnel C, Savard J, Ivers H: Cognitive impairments associated with breast cancer treatments: results from a longitudinal study.Breast Cancer Res Treat 2009, 116:113–123.
51. Rao SM, Leo GJ, Bernardin L, Unverzagt F: Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.Neurology 1991, 41:685–691.
52. Raudenbush S, Bryk A: Hierarchical Linear Models: Applications and Data Analysis Methods. SAGE Publications, Thousand Oaks, CA; 2002.
53. Raudenbush S, Bryk A, Cheong Y, Condon R: HLM 7: Linear and Nonlinear Modeling. Scientific Software International, Lincolnwood, IL; 2011.
54. Rolls ET, Grabenhorst F: The orbitofrontal cortex and beyond: from affect to decision-making.Prog Neurobiol 2008, 86:216–244.
55. Scherling C, Smith A: Opening up the window into “chemobrain”: a neuroimaging review.Sensors 2013, 13:3169–3203.
56. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith AM: Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study.Front Hum Neurosci 2011, 5:122.
57. Scherling C, Collins B, MacKenzie J, Lepage C, Bielajew C, Smith AM: Structural brain differences in breast cancer patients compared to matched controls prior to chemotherapy.Int J Biol 2012, 4:3.
58. Scherling C, Collins B, Mackenzie J, et al.: Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study.J Clin Exp Neuropsychol 2012, 34:543–560.
59. Seigers R, Schagen SB, Van Tellingen O, Dietrich J: Chemotherapy-related cognitive dysfunction: current animal studies and future directions.Brain Imaging Behav 2013, 7:453–459.
60. Silverman DHS, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy.Breast Cancer Res Treat 2007, 103:303–311.
61. Smith SM: Fast robust automated brain extraction.Hum Brain Mapp 2002, 17:143–155.
62. Smith SM, Nichols TE: Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.Neuroimage 2008, 44:83–98.
63. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady M, Matthews PM: Advances in functional and structural MR image analysis and implementation as FSL.Neuroimage 2004,23(Suppl 1):S208-S219.
64. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E: A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.Clin Neuropsychol 2006, 20:76–89.
65. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C: The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study.Psychooncology 2008, 17:122–130.
66. Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests. 3rd edition. Oxford University Press, New York; 2006.
67. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.Neuroimage 2002, 15:273–289.
68. Wechsler D: Wechsler Adult Intelligence Scale. 3rd edition. Harcourt, Brace, & Co., San Antonio, TX; 1997.
69. Wefel JS, Schagen SB: Chemotherapy-related cognitive dysfunction.Curr Neurol Neurosci Rep 2012, 12:267–275.
70. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.Cancer 2010, 116:3348–3356.
71. Wefel JS, Vardy J, Ahles T, Schagen SB: International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer.Lancet Oncol 2011, 12:703–708.
72. Yoshikawa E, Matsuoka Y, Inagaki M, Nakano T, Akechi T, Kobayakawa M, Fujimori M, Nakaya N, Akizuki N, Imoto S, Murakami K, Uchitomi Y: No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors.Breast Cancer Res Treat 2005, 92:81–84.
73. Yoshikawa E, Matsuoka Y, Yamasue H, Inagaki M, Nakano T, Akechi T, Kobayakawa M, Fujimori M, Nakaya N, Akizuki N, Imoto S, Murakami K, Kasai K, Uchitomi Y: Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis.Biol Psychiatry 2005, 59:707–712.